Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Radiation Research|January 27, 2018
Validating Baboon Ex Vivo and In Vivo Radiation-Related Gene Expression with Corresponding Human DataM Port, M Majewski, F Herodin, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|June 16, 2017
[Polymorphic variants of the immune response genes as risk factors for primary progressive multiple sclerosis]E V Popova, I S Kiselev, A N Boyko, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|February 17, 2022
[Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial]A N Boyko, O V Boyko, K Z Bakhtiyarova, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|January 15, 2020
[The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis]E P Evdoshenko, N A Neofidov, K Z Bakhtiyarova, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|August 31, 2018
[Primary-progressive multiple sclerosis in Russia: a medical-sociological study involving patients and neurologists]Ya V Vlasov, M V Churakov, M A Kurapov, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|February 27, 2023
[Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results]A N Boyko, K Z Bakhtiyarova, O V Boyko, et al.
Molecular Genetics and Metabolism|June 18, 2011
Polymorphic locus rs10492972 of the KIF1B gene association with multiple sclerosis in Russia: case control studyEkaterina A Kudryavtseva, Aleksei S Rozhdestvenskii, Anastasia V Kakulya, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|January 24, 2018
[Primary progressive multiple sclerosis: current issues of timely diagnosis]E V Popova, A N Boyko, M A Barabanova, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|April 21, 2023
[Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2]A N Boyko, V M Alifirova, I G Lukashevich, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|August 10, 2023
[Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS]A N Boyko, V M Alifirova, I G Lukashevich, et al.
Pageof 7